Skip to Content

Orbactiv Side Effects

Generic Name: oritavancin

Note: This document contains side effect information about oritavancin. Some of the dosage forms listed on this page may not apply to the brand name Orbactiv.

For the Consumer

Applies to oritavancin: intravenous powder for solution

Along with its needed effects, oritavancin (the active ingredient contained in Orbactiv) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking oritavancin:

Less common
  • Changes in skin color
  • dry, red, hot, or irritated skin
  • fast, pounding, or irregular heartbeat or pulse
  • pain, swelling, or tenderness in the skin
Less common or rare
  • Black, tarry stools
  • blistering, peeling, or loosening of the skin
  • fever
  • hives, itching skin, or rash
  • increase in bone pain
  • joint pain, stiffness, or swelling
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
  • redness, soreness, or itching skin
  • sores, welting, or blisters
  • swelling of the eyelids, face, lips, hands, or feet
  • swollen glands
  • tightness in the chest
  • unusual bleeding or bruising
Incidence not known
  • Abdominal or stomach tenderness
  • severe abdominal or stomach cramps and pain
  • watery and severe diarrhea, which may also be bloody

Some side effects of oritavancin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common or rare

For Healthcare Professionals

Applies to oritavancin: intravenous powder for injection


In pooled clinical trials, serious side effects were reported in 5.8% of patients treated with this drug (compared to 5.9% treated with vancomycin). Cellulitis was the serious side effect reported most often with both drugs. The most common side effects reported in patients treated with this drug were headache, nausea, vomiting, limb and subcutaneous abscesses, and diarrhea. This drug was discontinued due to side effects in 3.7% of patients; most often due to cellulitis and osteomyelitis.[Ref]


Common (1% to 10%): Nausea, vomiting, diarrhea
Frequency not reported: Clostridium difficile associated diarrhea[Ref]

Nervous system

Common (1% to 10%): Headache, dizziness[Ref]


Common (1% to 10%): Infusion site phlebitis, infusion site reaction, abscess (limb and subcutaneous)
Frequency not reported: Infusion related reactions (including pruritus, urticaria, flushing), osteomyelitis, infusion site erythema, extravasation, induration, peripheral edema[Ref]


Common (1% to 10%): Increased ALT, increased AST
Frequency not reported: Increased total bilirubin[Ref]


Common (1% to 10%): Tachycardia[Ref]


Frequency not reported: Cellulitis, pruritus, rash, urticaria, angioedema, erythema multiforme, pruritus, leukocytoclastic vasculitis[Ref]


Frequency not reported: Hypersensitivity reactions[Ref]


Frequency not reported: Anemia, eosinophilia[Ref]


Frequency not reported: Hyperuricemia, hypoglycemia[Ref]


Frequency not reported: Tenosynovitis, myalgia[Ref]


Frequency not reported: Bronchospasm, wheezing[Ref]


1. "Product Information. Orbactiv (oritavancin)." The Medicines Company, Parsippany, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.